Gracell Biotechnologies Companies
Gracell Biotechnologies is a pioneering organization in the field of cancer immune therapy. They develop cell therapies that deliver fast, deep, and durable responses for cancer and autoimmune disease patients. Their autologous platform produces CAR-T cell therapies that utilize next-day manufacturing to deliver younger, less exhausted T cells with enhanced activities. Additionally, their allogeneic platform generates CAR-T cell therapies that are readily available off-the-shelf at a lower cost for a broad patient base. Gracell Biotechnologies is also developing a 2nd generation enhanced CAR-T molecule to tackle the challenges in treating solid tumors. They have achieved significant milestones, including completing acquisitions, receiving FDA clearance for clinical trials, and gaining shareholders' approval of merger agreements.
